Global Endometriosis Drugs Market 2016-2020
About the Endometriosis Market
Endometriosis is a common health condition in women where the endometrial tissue, which is found in the lining of the uterus, appears and grows outside the uterine cavity. The endometrial tissue is shed from the body during menstruation.
The tissue growing outside the uterine cavity is called endometrial implants. Endometriosis can also occur in the fallopian tubes, ovaries, pelvic cavity, vagina, cervix, and bladder. In rare cases, it has been reported in other parts of the body such as the lungs, brain, and skin. These implants are usually benign in nature. Women of reproductive age are often affected by this condition.
Endometriosis often occurs due to retrograde menstruation, where the menstrual blood flows back into the pelvic cavity instead of leaving the body. This then adheres to the surface of the bladder, ovaries, or rectum and continues to grow or thicken over the course of each menstrual cycle.
Technavio’s analysts forecast the global endometriosis market to grow at a CAGR of 2.05% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global endometriosis market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of approved and off-label branded and generic drugs used for the treatment and prevention of endometriosis and related pain. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Endometriosis Market 2016-2020
Technavio recognizes the following companies as the key players in the global endometriosis market: AbbVie, AstraZeneca, Bayer HealthCare, and Pfizer.
Other Prominent Vendors in the market are: Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, Endoceutics, Euroscreen, Forendo Pharma, Isifer, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, ObsEva, Orphagen Pharmaceuticals, Philogen, PregLem, Repros Therapeutics, Roivant Sciences, SK Chemicals, Speciality European Pharma, SYNG Pharmaceuticals, Takeda, United Pharmaceuticals, and ValiPharma.
Commenting on the report, an analyst from Technavio’s team said: “A trend boosting market growth is the increased focus on IUDs. Current treatment for endometriosis includes the use of GnRH agonists and oral contraceptives along with the use of surgeries. However, all these therapies are associated with many unwanted side effects due to hormonal changes in the body along with the early recurrence of the disease. Hence, the need for an effective replacement for these conventional therapies has led to the development of IUDs. Though IUDs were initially developed for effective birth control, their use has been extended to treat endometriosis. Levonorgestrel intrauterine system (LNG-IUS) devices such as Mirena and Skyla will release progestogen into the body through the IUD at low concentration for an extended period.”
According to the report, a key growth driver is the increased adoption of OCPs. OCPs also referred to as hormonal pills contain the female hormones, estrogen and progestin similar to that produced by the ovaries. Some of the pills may contain only progestin. Apart from being used as contraceptives, these hormone pills are found to be effective in treating endometriosis. They do not cure endometriosis but are helpful in controlling the pain and preventing the condition from worsening. These medicines are also found to lower the chances of getting endometrial and ovarian cancer, ovarian cysts, certain breast lumps, and also protects the individual from osteoporosis.
Further, the report states that one challenge that could hamper market growth is surgery as the primary treatment option.
AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, Endoceutics, Euroscreen, Forendo Pharma, Isifer, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, ObsEva, Orphagen Pharmaceuticals, Philogen, PregLem, Repros Therapeutics, Roivant Sciences, SK Chemicals, Speciality European Pharma, SYNG Pharmaceuticals, Takeda, United Pharmaceuticals, ValiPharma.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook